Consonance Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Consonance Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,969,987	Closed	-$8.11M	–	33
2021 Q2	$8.11M	Sell	2,969,987 -216,348	-7%	-$538K	0.98%	19
2021 Q1	$8.32M	Hold	3,186,335	–	–	0.89%	24
2020 Q4	$8.86M	Sell	3,186,335 -50,000	-2%	-$146K	0.83%	26
2020 Q3	$15M	Sell	3,236,335 -416,968	-11%	-$1.38M	1.82%	18
2020 Q2	$10.3M	Hold	3,653,303	–	–	0.62%	27
2020 Q1	$8.91M	Buy	+3,653,303	New	+$13.2M	0.66%	28

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Consonance Capital Management's SIOX Position: Q3 2021 in Review

Consonance Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2021, closing a stake of 2,969,987 shares — an estimated $8.11M sold.

Consonance Capital Management first reported a position in SIOX in Q1 2020 and held it in 6 quarters. The position peaked at $15M in Q3 2020. 56 funds tracked by Wall St. Rank hold SIOX as of Q3 2021.

Consonance Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Consonance Capital Management sold 2,969,987 Sio Gene Therapies Inc. Common Stock shares in Q3 2021, an estimated $8.11M.
Consonance Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2020 and held it in 6 quarters.
Consonance Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $15M in Q3 2020.
56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.